Atuliflapon

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

AsthmaModerate-to-Severe Uncontrolled Asthma

Phase 2

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

CompletedNCT05251259

AstraZenecaAsthma

Start: 2022-01-27End: 2026-01-07Updated: 2026-01-14

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma

CompletedCTIS2023-509243-27-00

AstraZeneca ABModerate-to-Severe Uncontrolled Asthma

Start: 2023-04-12End: 2025-12-29Target: 431Updated: 2026-01-16